Archive for the ‘Lyme’ Category

Revolutionizing Lyme Disease Care for Patients

https://www.globallymealliance.org/blog/ravel-health?

Ravel Health is revolutionizing Lyme disease care with affordable, virtual, and personalized treatment options for chronic illness patients.

Perhaps you’ve been diagnosed with Lyme or other tick-borne illness. Maybe you’ve been suffering with chronic symptoms for years but have yet to receive a diagnosis. In either case, you want to see a Lyme literate medical provider (often referred to as LLMD), but you find yourself up against several barriers: wait-lists are months to years long. Providers don’t take insurance, and their rates are prohibitively expensive. You can’t find a provider in your area, and don’t have the energy or the means to travel. Sound familiar?

Chronic Lyme patients Kevin Williams and Jaime Intile know first-hand the frustrations that patients face in gaining access to treatment, so they’ve created a better way. Global Lyme Alliance is proud to partner with Williams and Intile’s company, Ravel Health, which specializes in matching patients with affordable, virtual care for Lyme, mold, and complex illness.

Available in ten states with the hope to be nationwide by 2025, Ravel Health offers subscription-based services that quickly match patients to vetted care teams who provide personalized telehealth including testing, treatment plans, prescriptions, and supplements.

“Ravel Health aims to simplify the Lyme journey from start to finish…”

“It can take a long time between onset of symptoms and diagnosis, and then getting a diagnosis is only half the battle,” Williams says. “We wanted to build something that we would have loved to have.” Unlike traditional medical practices, Ravel Health aims to simplify the Lyme journey from start to finish:

  • No medical gaslighting or saying “it’s all in your head”
  • No waitlists to see a vetted Lyme-literate provider
  • Personalized provider/patient matching
  • Conventional, Functional, and Integrative treatment options
  • Affordable 30, 60, or 90-minute monthly appointments with ability to upgrade or downgrade on a monthly basis
  • Significant discounts on labs and supplements
  • Everything done from the comfort of home

How does it work?

Ravel Health providers, including MDs, NDs, and NPs, go through a strict screening process. Each has at least six years of experience treating Lyme and chronic illness and is vetted through Williams and Intile themselves, and then through Ravel’s Chief Medical Officer.

After filling out a short questionnaire, patients are matched with up to three Lyme-literate providers in their state. Williams and Intile review initial questionnaires with the Chief Medical Officer to figure out the best possible fits based on individual patient preferences. Patients then choose from up to three providers. “We want patients to select providers based on fit, such as a provider’s specialties or treatment philosophy,” says Williams.

Patients also choose between affordable monthly subscription plans that offer different appointment lengths and intervals based on individual need. No matter the subscription, patients will always have ready access to providers, with guaranteed monthly appointments and guaranteed portal responses within three business days. “We believe deeply in continuity of care,” says Williams. “When a patient is having a flare, they need to be able to contact their provider or get an appointment booked. We want to make sure patients aren’t left hanging.”

Providers use evidence-supported labs and treatment protocols, personalizing them for each patient. Recommended test kits, lab orders, medications and supplements are sent directly to patient’s homes, with the option of mobile blood draws in certain areas. And Ravel Health’s simple model doesn’t just benefit patients. “We provide wraparound services so providers can focus on treatment,” Williams notes. Providers have a built-in community with whom they can share complex cases and ask questions.

What are patients saying?

Ravel Health ran a pilot from October to March with seven providers and thirty patients. The results were incredibly positive. Knowing that providers are vetted and curated, and knowing that they wouldn’t be medically gaslighted, put patients at ease. Patients know that Williams and Intile understand what they’re going through and have been through it themselves, so they trust they’re in good hands. “That piece is key for patients,” says Williams. He adds that having everything streamlined was refreshing for patients, as well as having options to choose from. Since Lyme and chronic illness strips patients of so much agency, Williams says, “We want to give patients as much choice as possible.”

Why Ravel?

Besides offering affordable, streamlined, and timely care from knowledgeable providers, Ravel focuses on the patient journey to health, as evidenced by the company’s name. With Lyme disease, life often unravels as patients fight for diagnosis, treatment, validation, and their health. Ravel Health helps patients ravel their health back together. “We are changing the way Lyme patients are treated,” says Williams.

To learn more about Williams and Intile, watch their episode on The Tick Chicks.

To learn more about Ravel Health, visit ravel.health

Ravel is available in CO, CT, IA, MN, MT, NE, PA, TX, WA & WI. To become a patient, go to https://ravel.health/get_started.

***

Another MSM Hit Piece – Lyme Disease: The ‘Yuppie Virus’ With Dangerous False Diagnoses

https://www.thetimes.com/world/us-world/article/lyme-disease-symptoms-serena-williams-alexis-ohainan-dltvc9pcb

Lyme disease: the ‘yuppie virus’ with dangerous false diagnoses

Half a million Americans say they have it — but a slew of celebrity cases is prompting a post-Covid rethink
Bevan Hurley

The Times

Alexis Ohanian, the co-founder of Reddit and husband of the tennis star Serena Williams, was perplexed.

He was showing no symptoms of Lyme disease, and had not spent much time in the wilderness or northeastern US states where the ticks that carry it are most prevalent. And yet, after a “full battery of health scans”, his doctor had told him that he was infected.

Ohanian, 41, who lives in Florida with Williams and their two children, revealed the diagnosis to his 560,000 followers on Twitter/X last month, saying it had taken him by surprise. He was careful to ensure that his personal experience would not be taken as medical advice. “Please talk to a doctor,” he said.  (See link for article)

________________

**Comment**

First off the bat, let’s be clear: MSM hasn’t done any thinking revolving anything about COVID.

Second – if you understand ‘controllers,’ you know that intervention is eventually needed when enough people start questioning the narrative.  Since people are talking about the fact there is an estimated 500,000 NEW cases of Lyme/MSIDS per year, it’s time for the spin-doctors to get busy.  Too many are questioning things.  Too many are asking to be tested.  Too many are getting fed up with doctors who gas-light them instead of helping them.

Enter MSM – a monolithic entity paid by Big Pharma which will do anything to protect its vested interests, including lie or distort facts.

Once you’ve seen it often enough you become aware of the thinly veiled journalism designed to make you doubt what you see with your own eyes, hear with your own ears, and even personally experience.

The article starts out by regurgitating well known disputed Lyme dogma:

  • can cause fever, chills, headache, fatigue, and muscle and joint aches
  • between 5-10% descend into PTLDS and get arthritis, chronic pain, heart palpitations, and brain inflammation

Let’s stop here and state emphatically that Lyme/MSIDS can and does kill people.  Let’s also state emphatically that this complex illness can destroy your life, income, family, and all you hold dear.

OK, now that we got that out of the way…..the article then states that ‘celebrity tell-alls and rampant pseudoscience’ is fueling misdiagnoses.

What about the thousands upon thousands that have been misdiagnosed for decades with virtually everything under the sun when they were infected with Lyme/MSIDS and immediate treatment could have made a real or THE difference?

The usual perps are presented for this angle: mainly representation from the American Lyme Disease Foundation (ALDF), who are known Lyme denialists.  This representative states practitioners are ‘unqualified’ because they have no infectious disease experience and are ‘cashing in’ by selling unreliable blood testing products and treatment.

This refrain is as old as time and is shear propaganda by controllers who want you to believe that only the government can protect consumers by monopolizing testing and treatment.  Well, they have done just that for over 40 years.  Let me ask you, ‘how’s that going?’  Nowhere, that’s where.

Particularly attacked were vitamin supplements and ozone therapy – two of the safest, most effective general treatments that help virtually everything!  But since the FDA can’t do any under the table deals with Big Pharma and make money off them, they are verboten!   

The article also hones in on ‘false positives,’ with Lyme but doesn’t utter a peep over the vast false positives with COVID, along with counting all deaths as COVID, that were purposely used to create a the illusion of vast cases and deaths.

Current Lyme testing is so flawed that a statistical analysis by Cook and Puri found that the LD two-tiered testing resulted in 500 times more false-negative outcomes than similar two-tiered tests used in the diagnosis of AIDS.  

The article also pushes the highly politicized climate change agenda when there is great controversy on many issues within this highly controlled paradigm, and independent research has shown it has nothing to do with tick proliferation or transmission.

While the article is at least honest enough to recognize that countries with nationalized health care struggle even more because there’s ‘there’s no system for them to go outside of,’ and that at least in the U.S. you can still find a doctor who is independent and can think for himself/herself.  But, how long will this last?

According to the author, the oft repeated belief that more funding to the same institutions that have denied Lyme/MSIDS from the get-go is somehow the answer, despite all evidence to the contrary.

Article grade: D

AMA Lyme Disease: A Clinician Toolkit (Part 2)

I must have missed Part 1.  Here it is:  https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249

In short, the CDC gave the AMA 5M in taxpayer dollars to come up with an IDSA Toolkit to improve care for patients with prolonged symptoms and concerns about Lyme disease.

Hopefully you can see the inherent problems with this.  Once again, the wolf is being asked how to take care of the chickens.  Dr. Paul Auwaerter particularly appears to speak out of both sides of his mouth.

Further, the American Medical Association (AMA) is a completely corrupt, tyrannical institution.  It opposes free speech, instructs doctors to deceive, is behind persecuting doctors who think for themselves, was found GUILTY in a court of law of conspiring against chiropractic, and has completely monopolized medicine with the help of the Rockefellers.

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32919062?

American Medical Association Lyme Disease: A Clinician Toolkit (Part 2)

Carl Tuttle
Hudson, NH, United States
Sep 25, 2024

The letter below is a follow-up to the previous petition update: https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “pauwaert@jhmi.edu” <pauwaert@jhmi.edu>, “pgauwaerter@gmail.com” <pgauwaerter@gmail.com>
Cc: “cbb0@cdc.gov” <cbb0@cdc.gov>, “jjohnson@genevausa.org” <jjohnson@genevausa.org>, “theerhisamariee@gmail.com” <theerhisamariee@gmail.com>, “jaucott@jhmi.edu” <jaucott@jhmi.edu>, “jraitt1@stanford.edu” <jraitt1@stanford.edu>, “dclauw@med.umich.edu” <dclauw@med.umich.edu>, “john.leong@tufts.edu” <john.leong@tufts.edu>, “avindra.nath@nih.gov” <avindra.nath@nih.gov>, “charles.chiu@ucsf.edu” <charles.chiu@ucsf.edu>, “elliot.cowan@partnersindiagnostics.com” <elliot.cowan@partnersindiagnostics.com>, “beth.jaworski@nih.hhs.gov” <beth.jaworski@nih.hhs.gov>, “roger@lundquist.org” <roger@lundquist.org>, “rachele.hendricks.sturrup@duke.edu” <rachele.hendricks.sturrup@duke.edu>, “info@lymebiobank.org” <info@lymebiobank.org>, “lorrainejohnson@outlook.com” <lorrainejohnson@outlook.com>, “wendyadams1@gmail.com” <wendyadams1@gmail.com>, “Leith.States@hhs.gov” <Leith.States@hhs.gov>, “tindall.matt@gmail.com” <tindall.matt@gmail.com>, “stacie.hudgens@clinoutsolutions.com” <stacie.hudgens@clinoutsolutions.com>, “raymond_dattwyler@nymc.edu” <raymond_dattwyler@nymc.edu>, “timothy.sellati@globallymealliance.org” <timothy.sellati@globallymealliance.org>, “nklimas@nova.edu” <nklimas@nova.edu>, “kester@genevausa.org” <kester@genevausa.org>, “nicole@nicolemalachowski.com” <nicole@nicolemalachowski.com>, “marcom@genevausa.org” <marcom@genevausa.org>, “stephen.gluckman@pennmedicine.upenn.edu” <stephen.gluckman@pennmedicine.upenn.edu>, “epocratesMedia@athenahealth.com” <epocratesMedia@athenahealth.com>, “epocrates@athenahealth.com” <epocrates@athenahealth.com>, “achen@mathematica-mpr.com” <achen@mathematica-mpr.com>, “info@mathematica-mpr.com” <info@mathematica-mpr.com>, “pdecker@mathematica-mpr.com” <pdecker@mathematica-mpr.com>, “lwx1@cdc.gov” <lwx1@cdc.gov>, “frederick.chen@ama-assn.org” <frederick.chen@ama-assn.org>, “gmarx@cdc.gov” <gmarx@cdc.gov>, “acoyne@mathematica-mpr.com” <acoyne@mathematica-mpr.com>, “jconstantine@mathematica-mpr.com” <jconstantine@mathematica-mpr.com>, “ctrenholm@mathematica-mpr.com” <ctrenholm@mathematica-mpr.com>, “tbarnes@mathematica-mpr.com” <tbarnes@mathematica-mpr.com>, “sboudreau@mathematica-mpr.com” <sboudreau@mathematica-mpr.com>, “jdevallance@mathematica-mpr.com” <jdevallance@mathematica-mpr.com>, “sara.berg@ama-assn.org” <sara.berg@ama-assn.org>, “jack.resneck@ucsf.edu” <jack.resneck@ucsf.edu>, “jack.resneck@ama-assn.org” <jack.resneck@ama-assn.org>, “todd.unger@ama-assn.org” <todd.unger@ama-assn.org>, “jon.burkhart@ama-assn.org” <jon.burkhart@ama-assn.org>, “karen.kmetik@ama-assn.org” <karen.kmetik@ama-assn.org>, “sanjay.desai@ama-assn.org” <sanjay.desai@ama-assn.org>, “aaguilar@webmd.net” <aaguilar@webmd.net>, “DFlapan@Medscape.net” <DFlapan@Medscape.net>, “lkane@medscape.net” <lkane@medscape.net>, “gamiller@medscape.net” <gamiller@medscape.net>, “dolmos@webmd.net” <dolmos@webmd.net>, “sarah.wright@webmd.net” <sarah.wright@webmd.net>, “editor2@webmd.net” <editor2@webmd.net>, “kg@kirstengillibrand.com” <kg@kirstengillibrand.com>, “yzhang207@zju.edu.cn” <yzhang207@zju.edu.cn>, “jonathan.kanter@usdoj.gov” <jonathan.kanter@usdoj.gov>, “Antitrust.ATR@usdoj.gov” <Antitrust.ATR@usdoj.gov>, “gheltzer@mwe.com” <gheltzer@mwe.com>, “albert.sambat@usdoj.gov” <albert.sambat@usdoj.gov>, “ddutko@rustyhardin.com” <ddutko@rustyhardin.com>, “kspeer@rustyhardin.com” <kspeer@rustyhardin.com>, “katrina.rouse@usdoj.gov” <katrina.rouse@usdoj.gov>, “loppenheimer@oppenheimer-law.com” <loppenheimer@oppenheimer-law.com>

Date: 09/25/2024 9:20 AM EDT
Subject: Re: Improving Care for Patients with Prolonged Symptoms and Concerns about Lyme Disease: A Clinician Toolkit

Dr Auwaerter,

While we wait for your reply to my previous inquiry dated Sept 2nd, I would like to call attention to the following publication you coauthored with Johns Hopkins colleague Dr. Ying Zhang in 2014:

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library – PubMed
Jie Feng, Ting Wang, Wanliang Shi, Shuo Zhang, David Sullivan, Paul G Auwaerter & Ying Zhang

https://pubmed.ncbi.nlm.nih.gov/26038747/

Excerpt:

Findings that suggest the continued presence of B. burgdorferi in some form indicate that current Lyme disease treatment may not sufficiently eliminate B. burgdorferi persisters or that the immune system fails to clear persisting organisms or bacterial debris, which may be the underlying cause for those who suffer from unresolved Lyme disease symptoms.
Recent quote from Dr. Ying Zhang: (Now with Zhejiang University School of Medicine, Hangzhou, Zhejiang, China)

“We’re dealing with a very unique situation here. The current Lyme antibiotic does not completely eradicate Borrelia bacteria. We found this dandelion phenomenon. The mower is equivalent to the antibiotics, that chopped off the top part. But because the root, the possessor, is still there, they can grow back. You need drugs targeting both parts in order to more effectively cure this persistent form of the disease.”

Dr Auwaerter,

These findings appear to be missing from your recorded interview on the AMA website: “Toolkit to Improve Care for Patients with Prolonged Symptoms and Concerns about Lyme Disease”

For the record there are seven published studies finding Dapsone effective in treating chronic Lyme disease as reported by Dr. Richard Horowitz and colleagues: 1, 2, 3, 4, 5, 6, 7

In contrast Dr. Auwaerter, you were the lead author who published the hit piece in the Lancet Infectious Diseases condemning these physicians:

Antiscience and ethical concerns associated with advocacy of Lyme disease (2011)
https://pubmed.ncbi.nlm.nih.gov/21867956/

The 5-million-dollar grant given to the AMA by the CDC for this so-called “Clinician Toolkit” would have been better spent on validating antimicrobials that cure chronic Lyme. But then again if we had the correct treatment who would opt for Pfizer’s Lyme vaccine currently in phase III clinical trials ready to roll out in 2026?

Questions:

Which CDC employee/academic stands to benefit financially (patent royalties etc.) from the soon to be released OspA Pfizer Lyme vaccine and what role have these individuals played (if any) in the ongoing collusion to deny chronic Lyme disease? 

Carl Tuttle
Independent Researcher
Hudson, NH

Cc: Assistant Attorney General Jonathan Kanter, Attorney Katrina Rouse
Attorneys for the United States Antitrust Division

Assistant Attorney General Jonathan Kanter Announces Task Force on Health Care Monopolies and Collusion
https://www.justice.gov/opa/pr/assistant-attorney-general-jonathan-kanter-announces-task-force-health-care-monopolies-and

References:

1. Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections.
https://pubmed.ncbi.nlm.nih.gov/37764145/

2. Effect of dapsone alone and in combination with intracellular antibiotics against the biofilm form of B. burgdorferi.
https://pubmed.ncbi.nlm.nih.gov/32993780/

3. Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.
https://pubmed.ncbi.nlm.nih.gov/35884166/

4. Combining Double-Dose and High-Dose Pulsed Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome and Co-Infections, Including Bartonella: A Report of 3 Cases and a Literature Review.
https://pubmed.ncbi.nlm.nih.gov/38792737/

5. Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review.
https://pubmed.ncbi.nlm.nih.gov/33105645/

6. Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1.
https://pubmed.ncbi.nlm.nih.gov/30863136/

7. Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2.
https://pubmed.ncbi.nlm.nih.gov/30400667/
Previous inquiry to Auwaerter dated Sept 2nd:
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249

When Lyme Patients Must Fight to be Believed by Doctors

https://www.lymedisease.org/lyme-patients-fight-to-be-believed/

When Lyme patients must fight to be believed by doctors

By Nancy Dougherty

Illness invalidation by medical professionals—sometimes called “gaslighting”—is an underappreciated and understudied problem in Lyme disease.

Many Lyme disease patients complain not only of fighting to recover their health but also of fighting to be believed by health care practitioners.

Expecting to receive understanding and proficient care from medical professionals, many instead experience having their persistent debilitating symptoms dismissed, minimized, disbelieved and/or psychologized.

How common is the occurrence of medical gaslighting in Lyme disease? Is illness invalidation by medical professionals related to disease severity? Are there specific constituencies who are being affected more than others?

These are some of the questions that a team of researchers led by Alison Rebman, MPH, Assistant Professor in Medicine and Director for Clinical and Epidemiological Research at the Johns Hopkins Lyme Disease Research Center at Johns Hopkins Medicine, set out to identify and quantify in a cohort of well-characterized Lyme disease patients.

Invalidating encounters

The Johns Hopkins study, published in August 2024 in Scientific Reports, finds that invalidating encounters with medical professionals are common for post-treatment Lyme disease (PTLD) patients, particularly women and younger patients, and also are linked to higher illness severity.

Lyme disease is the most common tick and vector-borne disease in the US with about 500,000 new cases per year. Lyme infections are expanding geographically, and acute and chronic cases are on the rise in the US and Eurasia. Lyme infection-associated chronic illness affects around 2 million Americans and can be difficult to properly diagnose and effectively treat.

A Lyme infection can affect multiple body systems including musculoskeletal, neurologic, and cardiovascular. Patients with early diagnosis and appropriate treatment usually get better. However, about 10-20% of patients even when treated promptly with standard of care antibiotics do not return to health and are functionally impaired by persistent musculoskeletal pain, crushing fatigue, and cognitive dysfunction, known in the research setting as post-treatment Lyme disease (PTLD).

Patients frequently refer to this as “chronic Lyme.” Misdiagnosis and delayed treatments further increase the risk for PTLD as well as for more broadly defined community-based Lyme infection-associated chronic illness or “chronic Lyme.”

Women and younger patients

In the Johns Hopkins study, 49% of the PTLD patients reported a lack of understanding and 29% experienced discounting from medical professionals. Additionally, women and younger patients were at higher risk for experiencing more invalidation than men or older age patients.

The study found, “Before their initial diagnosis of Lyme disease, approximately half (51.3%) had first been told that their symptoms represented another illness or condition. This high rate is consistent with the hypothesis that diagnosis and treatment delays, and possibly exposure to inappropriate treatment, may be risk factors for PTLD.”

Women more often received alternative diagnoses (such as another contested illness like fibromyalgia or ME/CFS and/or a psychological illness) which in turn correlated with more discounting and lack of understanding. PTLD patients who reported the highest levels of illness invalidation were discovered to have greater symptom severity, lower quality of life, and less trust in physicians.

The pervasiveness of Lyme disease illness invalidation and the consequential negative effects on illness burden and health outcomes are not broadly known by medical professionals.

Improved physician education is needed to help engender more patient-centered paradigms that incorporate the patient illness experience and better recognize how that experience may impact the healing process.

National Academies look at IACI

The National Academies of Sciences, Engineering and Medicine (NASEM) has helped validate infection- associated chronic illnesses as being significant public health problems that need greater national attention, a coordinated strategy, and considerably more federal resources.

NASEM held its first national workshop on infection-associated chronic illnesses (IACI) in June 2023 to explore overlapping symptoms and biologic pathways for IACIs including Lyme disease, long COVID, ME/CFS, MS, and others.

In July 2024, a follow-up NASEM meeting focused specifically on Lyme infection-associated chronic Illness. Both forums discussed the importance of listening to and incorporating patients’ illness experience perspectives into improving diagnostic and treatment approaches. For example, patient-driven data such as MyLymeData can be leveraged to improve research and clinical care. It is vital to listen to patients especially when diagnostics are problematic, treatments are inadequate, and the science is contested or evolving.

Building upon insights and collaborative momentum from the NASEM IACI meetings, a coalition of advocates (patient, scientific and medical) are now calling for the creation of a new National Institutes of Health (NIH) office to help strengthen and coordinate research across infection-associated chronic conditions and illnesses including Lyme infection-associated chronic illness, Long COVID, ME/CFS, PANS/PANDAS, POTS/dysautonomia and others.

Listening to patients will be key to advancing solutions, reducing invalidating patient-practitioner encounters, and improving health outcomes.

Nancy Dougherty is an education and communications consultant for the Johns Hopkins Lyme Disease Research Center. Other research investigations at the Center include Pilot Treatment Trials and the SLICE Studies.

_____________

For more:

Researchers Say New Lyme Test Can Detect Lyme Within 14 Days of Infection

https://www.lymedisease.org/detecting-lyme-within-14-days/

Researchers say this test can detect Lyme within 14 days of infection

Focus on Lyme and Aces Diagnostics Inc. has announced a breakthrough in Lyme disease diagnosis with a new test that detects the disease at all stages, including the crucial first 14 days post-infection, with over 90% accuracy.

Aces Diagnostics is developing and manufacturing this test, aiming for FDA clearance to make it accessible to all patients.

LymeSeek™, developed through a collaboration between Tulane University and Focus on Lyme, combines advanced biomarker research from Tulane’s Monica Embers and nine years of intensive work funded by Focus on Lyme. Enhanced by machine learning, this innovative diagnostic promises to reshape Lyme disease detection.

“Previous tests have been less than 50% accurate, especially in the early stages,” said Tammy Crawford, CEO of Aces Diagnostics. “This has led to countless patients being misdiagnosed or undiagnosed, resulting in prolonged suffering. LymeSeek will change that, providing a reliable diagnostic tool that can save lives.”

Aces Diagnostics Team

The CDC reports that nearly 500,000 people in the U.S. are diagnosed with Lyme disease each year. Globally, 14.5% of the population is affected, with many suffering from chronic symptoms due to delayed diagnosis. A Johns Hopkins study revealed that 38% of Lyme patients continue to experience symptoms six months post-diagnosis, underscoring the need for improved testing.

Simplifying diagnosis

“Current Lyme testing involves multiple steps, with results taking over a week and requiring subjective interpretation,” said Aces Diagnostics Co-Founder Holly Ahern.

“LymeSeek™ will replace this cumbersome process, enabling earlier diagnosis and reducing chronic illness caused by delayed or missed diagnoses.”

Crawford and Ahern are personally invested in this mission, both having daughters who battled Lyme disease. “An early diagnosis could have spared them years of suffering,” said Crawford.

Aces Diagnostics Inc. brings together a team with over 50 years of combined experience in Lyme disease research, backed by a distinguished advisory board that includes experts from Johns Hopkins University, Columbia University, and Tulane University. The company is already advancing development and manufacturing efforts and pursuing early FDA clearance to make LymeSeek™ available to the public by the third quarter of 2026.

SOURCE: Focus on Lyme

______________

**Comment**

Testing has been and continues to be a major problem with Lyme/MSIDS for numerous reasons, one of the biggest being the fact many are coinfected with numerous pathogens that mainstream medicine and research never discuss.  These coinfected patients are some of the sickest but are kicked to the curb because testing doesn’t reveal what’s inside them.

While this new test is a step in the right direction, it still doesn’t address those who have been infected for decades or those who are coinfected.  It’s like comparing apples to oranges and until these issues are addressed, it remains a foreign language to mainstream medicine.

The Johns Hopkins study showing nearly 40% go on to suffer symptoms 6 months post-diagnosis is still low in my opinion due to the fact so many are never diagnosed in the first place and so many are infected with multiple things that are never picked up on testing.

But, one must remain hopeful……

For more: